Metrics Contract Services begins $10M plant expansion
Clients set to benefit immediately through "higher yields" and "improved potent handling".
Metrics Contract Services, a full-service global contract development and manufacturing organization (CDMO) and a subsidiary of Mayne Pharma Group, has started constructing the expansion of its novel oral solid dosage manufacturing facility expansion in Greenville, North Carolina.
The $10-million investment will add 3,760 sq. ft of production space to the current facility, providing added flexibility and capacity to the CDMO and its clients.
The expansion consists of three new rooms: one dispensing/flex room, one tablet press room and one flex room to accommodate the company’s growing portfolio of commercial services following sustained increase in demand from clients for high potent handling capabilities.
New equipment also forms part of the investment and includes a Fette FE55 tablet press, a Bosch 720 encapsulator, which both offer containment capabilities for the safe handling of potent products, and a weigh and dispense isolator.
The new equipment is ideal for the small batch size and high changeover products which the company's clients require. John Ross, President at Mayne Pharma US and Metrics Contract Services, said: “Our clients will see immediate benefits through higher yields and improved potent handling.”
The company said it recognized that customers' commercial requirements often demanded increased flexibility within production suites. This expansion will cater for those needs by creating more spaces where equipment trains can be tailored to the applicable process.
The expansion project which has been in development over the last 6 months is expected to be complete and fully operational by February 2021.
Ross added: “This is a significant investment for the business and reflects our commitment to increasing our novel oral solid manufacturing capabilities and providing our clients with quality services from initial concept through to global commercialization."
The company is now actively considering the next phase of investment, which may include further packaging and adjacent formulation technologies.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance